Skip to main content

Celmatix Partners With Onctotest-Teva to Offer Reproductive Health Genetic Test in Israel

NEW YORK (GenomeWeb) – Celmatix said today that it has partnered with Oncotest-Teva, a subsidiary of Teva Pharmaceutical Industries, to make Celmatix's Fertilome genetic test for reproductive health and fertility available in Israel.

The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility, including recurrent pregnancy loss, primary ovarian insufficiency, endometriosis, and polycystic ovary syndrome.

"By gaining an early understanding of their risk of developing conditions that could affect their fertility and reproductive health with the Fertilome test, women in Israel can make more informed choices that may ultimately improve their own outcomes, either by trying on their own or pursuing treatment sooner than they may have otherwise," said Lior Soussan-Gutman, managing director at Oncotest-Teva, in a statement.

Israel's per capita use of in vitro fertilization treatments is high, making it "an ideal market for the first international expansion of the Fertilome test, and we look forward to seeing the impact it will have as women and their doctors make decisions informed by genomic insights," Piraye Yurttas Beim, founder and CEO of New York-based Celmatix, said in the statement.